## DISCLOSURES AND RESOLUTION OF CONFLICT OF INTEREST

The following faculty members have indicated that they do not have any relevant financial relationships with ineligible companies\* to disclose. \*\*Indicates that this individual's presentation(s) <u>will include</u> discussion of off-label or unapproved usage.

Larry M. Bush, M.D., FACP Ravi Durvasula, M.D. Jeremy S. Faust, M.D. Margaret Johnson, M.D. Warren L. Kupin, M.D.

Fred Kusumoto, M.D.
Melissa Lyle, M.D.
Salvatore Mangione, M.D.
Michael B. Phillips, M.D., FACP
William Sanchez, M.D.

Marwan Shaikh, M.D. Ayalew Tefferi, M.D. \*\* Benjamin Wang, M.D.

The following faculty members have indicated that they do have relevant financial relationships with ineligible companies\* to disclose.

**Kenneth Rosenthal, M.D.,** symposium director, has indicated that he is a member of the Speakers' Bureau for AbbVie pharmaceuticals.

**John F. Rubin, M.D., FACP,** symposium director, has indicated that he is a shareholder in Astrazeneca and Bristol Myers Squibb.

**Jessica Allegretti, M.D.,** faculty for this educational activity, has indicated that she is a consultant for Janssen, Pfizer, AbbVie, Bristol Myers Squibb, Merck, Servatus, Pandion, and Morphic. Dr. Allegretti has also indicated that she is a speaker for Bristol Myer Squibb and an Independent Contractor for Merck, Pfizer, and Janssen.

**Jodie Barkin, M.D.,** faculty for this educational activity, is a consultant for AbbVie, Nestle Health Sciences, HealthiVibe/CorEvitas, Envara Health and Medtronics. He also receives Unrestricted Educational Grants (Prior) from AbbVie, Cook Endoscopy and Career Development Grant: Cystic Fibrosis Foundation DIGEST Grant. Dr. Barkin has indicated that the presentation or discussion will not include off-label or unapproved product usage.

**Michael J. Blaha, M.D., MPH,** faculty for this educational activity, has indicated that he is a researcher for Bayer, Novo Nordisk, and Amgen. Dr. Blaha has also indicated that he is a consultant for Kowa and Emocah, an adviser for Amgen, Novartis, Novo Nordisk, Bayer, Roche, 89BIO, Kaleido, and Inozyme, and an independent contractor for Bayer, Novo Nordisk, and Amgen.

Olga Fermo, M.D., faculty for this educational activity, has also indicated that she is a speaker for Allergan and Biohaven.

**Devin Steenkamp, M.D.**, faculty for this educational activity, has indicated that he is a researcher for Novo Nordisk and Mylan Pharmaceuticals. Dr. Steenkamp has also indicated that he is a consultant for Lilly Innovations.

Ryan Uitti, M.D., faculty for this educational activity, has indicated that he is a researcher for Boston Scientific.

All of the relevant financial relationships listed for these individuals have been mitigated.

Other individuals involved in planning, content review, approval, or moderating for this educational activity have no relevant financial relationships to disclose with ineligible companies\*.

<sup>\*</sup>Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.